Written Authority Required Drugs

Non-radiographic axial spondyloarthritis

The Pharmaceutical Benefits Scheme (PBS) subsidises golimumab for patients with non-radiographic axial spondyloarthritis.

Patient eligibility

The PBS subsidises treatment with golimumab under the National Health Act 1953, section 85 for patients with non-radiographic axial spondyloarthritis.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing golimumab.

Treatment specifics

Patients must be treated by a rheumatologist or clinical immunologist with expertise managing non-radiographic axial spondyloarthritis to be eligible for PBS subsidised treatment with golimumab.

Applications

Initial treatment

Apply for initial authority approval to prescribe PBS subsidised golimumab to treat non-radiographic axial spondyloarthritis in writing and either:

All applications must include the completed:

Initial grandfather treatment

For patients who received non-PBS subsidised golimumab before 1 December 2018 for non-radiographic axial spondyloarthritis, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Continuing or recommencing treatment

Apply for authority approval to continue or recommence PBS subsidised golimumab to treat non-radiographic axial spondyloarthritis in writing and either:

All applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 22 February 2019